AstraZeneca logo

AZN - AstraZeneca News Story

7031p -153.0  -2.1%

Last Trade - 11:45am

Sector
Healthcare
Size
Large Cap
Market Cap £94.27bn
Enterprise Value £105.29bn
Revenue £19.94bn
Position in Universe 6th / 1834

AstraZeneca PLC - Director/PDMR Shareholding

Wed 19th February, 2020 7:00am
RNS Number : 3828D
AstraZeneca PLC
19 February 2020
 

19 February 2020 07:00 GMT

 

 

TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES

Disclosure under Article 19 of the EU Market Abuse Regulation

 

AstraZeneca PLC (the Company) announces that, on 17 February 2020, it was notified by Michel Demaré, a Non-Executive Director of the Company, that, on 17 February 2020, Mr Demaré purchased 700 Ordinary Shares of $0.25 each in the Company (Shares) at a price of £73.13 per Share.

 

The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Michel Demaré

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Non-Executive Director

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

AstraZeneca PLC

b)

 

LEI

 

 

PY6ZZQWO2IZFZC3IOL08

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Ordinary Shares of US$0.25 each in AstraZeneca PLC

 

 

GB0009895292

 

b)

 

Nature of the transaction

 

 

Share purchase

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

GB£73.13

700

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

Not applicable - single transaction

 

e)

 

Date of the transaction

 

 

17 February 2020

f)

 

Place of the transaction

 

 

XLON

 

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, CVRM, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.

 

 

Media Relations

 

 

Gonzalo Viña

 

+44 203 749 5916

Rob Skelding

Oncology

+44 203 749 5821

Rebecca Einhorn

Oncology

+1 301 518 4122

Matt Kent

BioPharmaceuticals

+44 203 749 5906

Jennifer Hursit

Other

+44 203 749 5762

Christina Malmberg Hägerstrand

Sweden

+46 8 552 53 106

Michele Meixell

US

+1 302 885 2677

 

 

 

Investor Relations

 

 

Thomas Kudsk Larsen

 

+44 203 749 5712

Henry Wheeler

Oncology

+44 203 749 5797

Christer Gruvris

BioPharmaceuticals (cardiovascular; metabolism)

+44 203 749 5711

Nick Stone

BioPharmaceuticals (respiratory; renal)

+44 203 749 5716

Josie Afolabi

Other medicines

+44 203 749 5631

Craig Marks

Finance, fixed income

+44 7881 615 764

Jennifer Kretzmann

Corporate access, retail investors

+44 203 749 5824

US toll-free

 

+1 866 381 72 77


Adrian Kemp
Company Secretary
AstraZeneca PLC


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHUWSVRRAUUAAR
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.